Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celcuity, Inc. (CELC : NSDQ)

• Company Description    Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. Number of Employees: 87

• Price / Volume Information    Yesterday's Closing Price: $50.03 Daily Weekly Monthly 20 Day Moving Average: 1,049,789 shares Shares Outstanding: 42.43 (millions) Market Capitalization: $2,122.61 (millions) Beta: 0.70 52 Week High: $63.06 52 Week Low: $7.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.37% -9.34% 12 Week 256.08% 239.42% Year To Date 282.20% 236.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 16305 36TH AVENUE NORTH SUITE 100 - MINNEAPOLIS,MN 55446 USA ph: 763-392-0767 fax: - None http://www.celcuity.com

• General Corporate Information    Officers Brian F. Sullivan - Chief Executive Officer and Chairman Vicky Hahne - Chief Financial Officer Lance G. Laing - Vice President and Secretary and Director Richard E. Buller - Director Dave F. Dalvey - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15102K100 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 42.43 Most Recent Split Date: (:1) Beta: 0.70 Market Capitalization: $2,122.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 43.87 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -67.74% vs. Previous Quarter: -20.93% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -150.07 03/31/25 - -96.21 ROA 09/30/25 - - 06/30/25 - -64.67 03/31/25 - -49.44 Current Ratio 09/30/25 - - 06/30/25 - 4.58 03/31/25 - 6.61 Quick Ratio 09/30/25 - - 06/30/25 - 4.58 03/31/25 - 6.61 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 1.14 03/31/25 - 2.29 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 2.24 03/31/25 - 1.14 Debt-to-Capital 09/30/25 - - 06/30/25 - 69.11 03/31/25 - 53.20

Powered by Zacks Investment Research ©